J&J’s Biosense Webster Names Jasmina Brooks as President

Johnson & Johnson MedTech company Biosense Webster has named Jasmina (Jass) Brooks as its new president.
 
In this role, Brooks will be accountable for setting Biosense Webster’s global strategy and advancing innovation agenda. Brooks succeeds Michael Bodner, Ph.D., who has assumed the role of global head of Heart Recovery for Johnson & Johnson MedTech.
 
Brooks has almost 25 years’ experience in the cardiovascular field, mainly focused on electrophysiology. She’s a nine-year veteran of Biosense Webster, and was most recently VP of global strategic marketing for the company. She joined Biosense Webster in 2014 and had positions of increasing scope and responsibility in its strategic marketing organization.
 
Prior to Johnson & Johnson, Brooks spent 15 years at GE Healthcare, where she had several roles in commercial marketing, global strategic marketing, product development, and engineering in the U.S. and EMEA regions.
 
“Jass Brooks is a well-respected, collaborative leader with a deep knowledge of the electrophysiology space, a track record of successfully driving growth and market leadership, as well as a deep commitment to developing talent and fostering a culture of collaboration and inclusivity,” Celine Martin, Company Group Chairman, Cardiovascular & Specialty Solutions Group, Johnson & Johnson, told the press. “Jass has dedicated her career to championing excellence in patient outcomes and solving unmet medical needs, and she will continue to harness this passion in leading Biosense Webster as the company advances innovation solutions to help people with Afib live the lives they want.” 
 
“It is an honor to lead Biosense Webster, with its proud legacy and unmatched capabilities in cardiac catheter ablation,” said Brooks. “I look forward to continuing to partner closely with the electrophysiology community to elevate standards of care in AFib.”